Background
Methods
Definition and selection of cases
Clinicopathological study
Tissue Microarray construction
Markers and immunohistochemistry
Protein (Clone) | Antibody | Origin | Clone | Pre-treatment | Dilution | Location of staining | Normal |
---|---|---|---|---|---|---|---|
Caveolin 1 | mmb | Santa Cruz | N20 | Micro waves (10 min), tps citrate pH = 6 | 1/1000 | cytoplasm | m.e.c+ |
Caveolin 2 | mmb | Transduction Laboratories | 65 | Target retrival solution (98°C, 40 min) | 1/50 | cytoplasm | m.e.c+ |
Cytokeratin 5/6 | mmb | Dako | D5/16 B4 | Target retrival solution (98°C, 40 min) | 1/10 | cytoplasm | m.e.c + |
Cytokeratin 14 | mmb | Newcastle UK | LL002 | Target retrival solution (98°C, 40 min) | 1/300 | Cell membrane | m.e.c+ |
EGFR | mmb | Zymed | 3IG7 | Target retrival solution (98°C, 40 min) | 1/10 | membrane | m.e.c + |
ERBB2 | mmb | Dako Herceptest Ltd | AO485 | Target retrival solution (98°C, 40 min) | 1/500 | membrane | - |
Estrogen receptor (ER) | mmb | Novocastra laboratories Ltd | 6F11.2 | Target retrival solution (98°C, 40 min) | 1/60 | nucleus | m.e.c- and luminal+ |
P53 | mmb | Dako | DO-1 | Target retrival solution (98°C, 40 min) | 1/4 | nucleus | - |
P-cadherin | mmb | Transduction laboratories | 56 | Target retrival solution (98°C, 40 min) | 1/75 | Cell membrane | m.e.c + |
Progesterone receptor (PR) | mmb | Dako | PFR 636 | Target retrival solution (98°C, 40 min) | 1/80 | Nucleus | m.e.c- and luminal+ |
Ki67 | mmb | Dako | KI-67 | Target retrival solution (98°C, 40 min) | 1/100 | Nuclear | - |
MUC1 | mmb | Transgen | H23 | none | 1/1000 | Apical/Cytoplamic | + |
Statistical analysis
Results
Characteristics of patients and tumors
Variables | IBC | Non-IBC | p |
---|---|---|---|
Age | |||
Min | 22 | 25 | |
Max | 76 | 94 | <0.001 |
Mean | 43.47 | 59.43 | |
Standard deviation | 9.43 | 12.77 | |
Grade | |||
I | 3(3.3%) | 176(32.41%) | |
II | 60(65.93%) | 229(42.17%) | <0.001 |
III | 28(30.77%) | 138(25.41%) * | |
Histological type | |||
Invasive ductal carcinoma | 86(94.5) | 386(70.56) | |
Micropapillary carcinoma | 5(5.5) | 0 | |
Lobular carcinoma | 0 | 72(13.16) | |
Tubular carcinoma | 0 | 37(6.76) | <0.001 |
Mixt | 0 | 24(4.38) | |
Medullary carcinoma | 0 | 8(1.46) | |
Others | 0 | 20(3.65) |
Protein expression profiles of IBC and non-IBC and immunohistochemical subtypes
IBC | Non-IBC | p value | ||
---|---|---|---|---|
n (%) | n (%) | |||
ER | Negative | 42 (53.85%) | 99 (26.26%) | <0.001 |
Positive | 36 (46.15%) | 278 (73.74%) | ||
PR | Negative | 37 (52.86%) | 132 (35.39%) | <0.01 |
Positive | 33 (47.14%) | 241 (64.61%) | ||
ERBB2 | 0–1 | 48 (66.67%) | 301 (85.51%) | <0.001 |
2–3 | 24 (33.33%) | 51 (14.49%) | ||
EGFR | Negative | 57 (77.03%) | 240 (75.24%) | >0.05 |
Positive | 17 (22.97%) | 79 (24.76%) | ||
CK5/6 | Negative | 47 (61.04%) | 191 (67.25%) | >0.05 |
Positive | 30 (38.96%) | 93 (32.75%) | ||
CK14 | Negative | 38 (80.85%) | 295 (94.55%) | <0.01 |
Positive | 9 (19.15%) | 17 (5.45%) | ||
P-cadherin | Negative | 13 (24.07%) | 169 (51.84%) | <0.001 |
Positive | 41 (75.93%) | 157 (48.16%) | ||
P53 | Negative | 43 (58.11%) | 253 (69.7%) | >0.05 |
Positive | 31 (41.89%) | 110 (30.3%) | ||
MUC1 | Negative | 5 (6.67%) | 42 (12.84%) | >0.05 |
Positive | 70 (93.33%) | 285 (87.16%) | ||
CAV1 | Negative | 22 (31.43%) | 105 (31.16%) | >0.05 |
Positive | 48 (68.57%) | 232 (68.84%) | ||
CAV2 | Negative | 45 (90%) | 212 (89.83%) | >0.05 |
Positive | 5 (10%) | 35 (10.17%) | ||
MIB1 | ≤20 | 43 (58.9%) | 295 (87.02%) | <0.001 |
>20 | 30 (41.1%) | 44 (12.98%) |
IBC | Non-IBC | ||
---|---|---|---|
n (%) | n (%) | p value | |
Basal cases (ER-, ERBB2-) | 24 (33.8%) | 58 (15.93%) | <0.001 |
ERBB2-overexpressing cases | 24 (33.33%) | 51 (14.49%) | <0.001 |
Luminal cases (ER+, PR+) | 22 (29.33%) | 221 (58.93%) | <0.001 |
Expression of P-cadherin in IBC and non-IBC
Univariate analyses
IBC | Non-IBC | p-value | |
---|---|---|---|
n(%) | n(%) | ||
Basal cases (ER-,ERBB2-) | 18/19(95%) | 35/51(69%) | 0.05 |
ERBB2-overexpressing cases | 9/13(69%) | 32/47(68%) | NS |
Luminal cases (ER+, PR+) | 14/17(82%) | 84/197(43%) | <0.01 |
Multivariate analyses
With histoprognostic factors | Regression coefficient | OR | p | Without histoprognostic factors | Regression coefficient | OR | p |
---|---|---|---|---|---|---|---|
Grade (II-III) | 1.84 | 6.28 | 0.081 | P-cadherin >0 | 1.59 | 4.90 | 0.001 |
P-cadherin >0 | 1.44 | 4.21 | 0.013 | MIB 1 >20 | 1.28 | 3.60 | 0.001 |
MIB1 >20 | 1.04 | 2.82 | 0.018 | CK14 >0 | 1.02 | 2.79 | 0.028 |
ER <0 | -0.87 | 1.00 | 0.053 | ERBB2 (2–3) | 0.84 | 2.34 | 0.063 |